Lupin has launched Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) having received an approval from the United States Food and Drug Administration (USFDA) earlier. Minastrin 24 Fe chewable tablets had US sales of $360.5 million as per IMS MAT December 2016.
Lupin’s Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) is the AB rated generic equivalent of Allergan Pharmaceuticals International’s Minastrin 24 Fe Tablets. It is indicated for use by females of reproductive age to prevent pregnancy.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
